

Syncona has a world-leading late-stage clinical portfolio developing products with the potential to treat patients across a range of diseases.
The SIML team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across Syncona’s late-stage clinical companies.
Unless stated all financials at 31 March 2025
Value of late-stage clinical and commercial portfolio
Number of clinical trials
Portfolio company Board seats